Advertisement

Osteoporosis International

, Volume 23, Issue 1, pp 75–85 | Cite as

Fracture risk assessment without bone density measurement in routine clinical practice

  • W. D. LeslieEmail author
  • S. Morin
  • L. M. Lix
  • H. Johansson
  • A. Oden
  • E. McCloskey
  • J. A. Kanis
  • for the Manitoba Bone Density Program
Original Article

Abstract

Summary

Fracture probability assessed without bone mineral density (BMD) could potentially be sufficient for clinical decision making in many individuals categorized as low or high fracture risk. For individuals falling in a moderate risk range, there is incremental value in using BMD in the probability calculation as this appropriately reclassifies risk in over one third of the individuals.

Introduction

A new fracture risk assessment tool from the World Health Organization (FRAX®) estimates 10-year major osteoporotic and hip fracture probabilities from multiple clinical risk factors with or without hip BMD. The objective of this study is to determine whether fracture probability derived without BMD can be used to identify individuals who would be designated for treatment.

Methods

A historical cohort of 36,730 women and 2,873 men aged 50 years and older drawn from the Manitoba Bone Density Program database, which contains clinical BMD results for the Province of Manitoba, Canada, was included in the study.

Results

When 10-year probability for major osteoporotic fracture estimated without knowledge of BMD was high (≥20%), the vast majority (92.8%) qualified for intervention under the National Osteoporosis Foundation (NOF) guidelines, whereas among those at low risk (<10%), the vast majority (80.5%) did not satisfy any NOF intervention criteria. The benefit of including BMD in the risk assessment was greatest among those initially at moderate risk (10–19%) when fracture probability was derived without BMD, but this represented only 29.4% of the cohort (9.3% of those aged <65 years and 48.7% of those ≥65 years).

Conclusions

Fracture probability derived without BMD is able to risk stratify women in terms of future fracture risk and could potentially be sufficient for clinical decision making in many of those designated at low or high fracture risk.

Keywords

Administrative data Bone mineral density Dual-energy X-ray absorptiometry Fracture prediction FRAX Osteoporosis 

Notes

Acknowledgments

We are indebted to Manitoba Health for providing data (HIPC File No. 2007/2008-35). The results and conclusions are those of the authors, and no official endorsement by Manitoba Health is intended or should be inferred. This article has been reviewed and approved by the members of the Manitoba Bone Density Program Committee.

Conflicts of interest

William Leslie received unrestricted research grants from Merck Frosst, Amgen, and Genzyme and research honoraria and unrestricted educational grants from Sanofi-Aventis, Warner-Chilcott/Procter & Gamble, and Novartis. He is also a member of the advisory boards of Genzyme, Novartis, and Amgen. Lisa Lix received an unrestricted research grant from Amgen. Suzanne Morin is a consultant to Warner-Chilcott/Procter & Gamble, Sanofi-Aventis, Amgen, and Novartis. She is also a member of the speaker bureau of Amgen and Novartis. Eugene McCloskey received speaker fees and/or unrestricted research grants from Novartis, Amgen, AstraZeneca, Pfizer, Bayer, Warner-Chilcott/Procter & Gamble, Lilly, Roche, Servier, and Hologic. John A Kanis serves as director of the WHO Collaborating Centre for Metabolic Bone Diseases. Dr. Kanis led the team that developed FRAX; he has no financial interest in FRAX. Dr. Kanis has served as a consultant to Abiogen, Italy; Amgen, USA, Switzerland, and Belgium; Bayer, Germany; Besins-Iscovesco, France; Biosintetica, Brazil; Boehringer Ingelheim, UK; Celtrix, USA; D3A, France; the European Federation of Pharmaceutical Industries and Associations; Gador, Argentina; General Electric, USA; GSK, UK and USA; Hologic, Belgium and USA; Kissei, Japan; Leo Pharma, Denmark; Lilly, USA, Canada, Japan, Australia, and UK; Merck Research Labs, USA; Merlin Ventures, UK; MRL, China; Novartis, Switzerland and USA; Novo Nordisk, Denmark; Nycomed, Norway; Ono, UK and Japan; Organon, Holland; Parke-Davis, USA; Pfizer, USA; Pharmexa, Denmark; Procter and Gamble, UK and USA; ProStrakan, UK; Roche, Germany, Australia, Switzerland, and USA; Rotta Research, Italy; Sanofi-Aventis, USA; and Schering, Germany and Finland. He has provided expert testimony for the High Court (UK). His institution has received grants from the Medical Research Council (UK), the Arthritis and Rheumatism Council (UK), and the European Federation of Pharmaceutical Industries and Associations. He has received speaker’s fees from Amgen, Novartis, and Servier. He has also worked with the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, the Government of Manitoba, the Group for the Respect of Ethics and Excellence in Science, INSERM (France), the Medical Research Council (UK), the Ministry of Public Health of China, the Ministry of Health of Australia, the National Institute for Health and Clinical Excellence (UK), the National Osteoporosis Guideline Group (UK), the National Osteoporosis Society (UK), the International Osteoporosis Foundation, the Japanese Osteoporosis Society, Osteoporosis 2000 (UK), Osteoporosis Australia, the Swiss Osteoporosis Society, and the WHO. The other authors do not have any conflicts of interest to declare.

Supplementary material

198_2011_1747_MOESM1_ESM.doc (16 kb)
Supplementary Table 1 Area under the curve (AUC) for fracture prediction. (DOC 15.5 kb)
198_2011_1747_MOESM2_ESM.doc (40 kb)
Supplementary Table 2 Proportion of individuals satisfying intervention criteria according to risk categorization from hip fracture probability without BMD. (DOC 39.5 kb)
198_2011_1747_MOESM3_ESM.doc (202 kb)
Supplementary Fig. 1 Receiver operating characteristic curves for identification of individuals meeting intervention criteria using major osteoporotic fracture probability (dark) and hip fracture probability (light) calculated without BMD. (DOC 202 kb)

References

  1. 1.
    NIH Consensus Development Panel (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRefGoogle Scholar
  2. 2.
    Wiktorowicz ME, Goeree R, Papaioannou A et al (2001) Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 12:271–278PubMedCrossRefGoogle Scholar
  3. 3.
    Papaioannou A, Wiktorowicz ME, Adachi JD et al (2000) Mortality, independence in living and re-fracture, one year following hip fracture in Canadians. J Soc Obstet Gynaecol Can 22:591–597Google Scholar
  4. 4.
    Kanis JA, Oden A, Johnell O et al (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427PubMedCrossRefGoogle Scholar
  5. 5.
    Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581–589PubMedCrossRefGoogle Scholar
  6. 6.
    Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report, WHO Collaborating Centre for metabolic Bone Disease, University of Sheffield, UK. Available at http://www.shef.ac.uk/FRAX
  7. 7.
    Kanis JA, Johnell O, Oden A et al (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397PubMedCrossRefGoogle Scholar
  8. 8.
    Dawson-Hughes B (2008) A revised clinician’s guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93:2463–2465PubMedCrossRefGoogle Scholar
  9. 9.
    Dawson-Hughes B, Tosteson AN, Melton LJ III et al (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449–458PubMedCrossRefGoogle Scholar
  10. 10.
    Kanis JA, McCloskey EV, Johansson H et al (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408PubMedCrossRefGoogle Scholar
  11. 11.
    Lippuner K, Johansson H, Kanis JA et al (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–389PubMedCrossRefGoogle Scholar
  12. 12.
    Kanis JA, Burlet N, Cooper C et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRefGoogle Scholar
  13. 13.
    Fujiwara S, Kasagi F, Masunari N et al (2003) Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18:1547–1553PubMedCrossRefGoogle Scholar
  14. 14.
    Neuprez A, Johansson H, Kanis JA et al (2009) A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liege 64:612–619PubMedGoogle Scholar
  15. 15.
    Papaioannou A, Morin S, Cheung AM et al (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873PubMedCrossRefGoogle Scholar
  16. 16.
    Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRefGoogle Scholar
  17. 17.
    Leslie WD, MacWilliam L, Lix L et al (2005) A population-based study of osteoporosis testing and treatment following introduction of a new bone densitometry service. Osteoporos Int 16:773–782PubMedCrossRefGoogle Scholar
  18. 18.
    Leslie WD, Caetano PA, MacWilliam LR et al (2005) Construction and validation of a population-based bone densitometry database. J Clin Densitom 8:25–30PubMedCrossRefGoogle Scholar
  19. 19.
    Kanis JA, McCloskey EV, Johansson H et al (2008) A reference standard for the description of osteoporosis. Bone 42:467–475PubMedCrossRefGoogle Scholar
  20. 20.
    Hansen KE, Binkley N, Christian R et al (2005) Interobserver reproducibility of criteria for vertebral body exclusion. J Bone Miner Res 20:501–508PubMedCrossRefGoogle Scholar
  21. 21.
    Roos NP, Shapiro E (1999) Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care 37:JS10–JS14PubMedCrossRefGoogle Scholar
  22. 22.
    Kozyrskyj AL, Mustard CA (1998) Validation of an electronic, population-based prescription database. Ann Pharmacother 32:1152–1157PubMedCrossRefGoogle Scholar
  23. 23.
    Leslie WD, Tsang JF, Caetano PA et al (2007) Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 92:77–81PubMedCrossRefGoogle Scholar
  24. 24.
    Leslie WD, Lix LM, Johansson H et al (2010) Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 25:2350–2358PubMedCrossRefGoogle Scholar
  25. 25.
    Fraser LA, Langsetmo L, Berger C et al (2011) Fracture prediction and calibration of a Canadian FRAX(R) tool: a population-based report from CaMos. Osteoporos Int 22:829–837PubMedCrossRefGoogle Scholar
  26. 26.
    Siminoski K, Leslie WD, Frame H et al (2005) Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J 56:178–188PubMedGoogle Scholar
  27. 27.
    Tosteson AN, Melton LJ III, Dawson-Hughes B et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447PubMedCrossRefGoogle Scholar
  28. 28.
    Tosteson AN, Burge RT, Marshall DA et al (2008) Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care 14:605–615PubMedGoogle Scholar
  29. 29.
    Satagopan JM, Ben-Porat L, Berwick M et al (2004) A note on competing risks in survival data analysis. Br J Cancer 91:1229–1235PubMedCrossRefGoogle Scholar
  30. 30.
    Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr et al (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172PubMedCrossRefGoogle Scholar
  31. 31.
    Janes H, Pepe MS, Gu W (2008) Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 149:751–760PubMedGoogle Scholar
  32. 32.
    Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238PubMedCrossRefGoogle Scholar
  33. 33.
    Curtis JR, Laster A, Becker DJ et al (2009) The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States. Osteoporos Int 20:1553–1561PubMedCrossRefGoogle Scholar
  34. 34.
    Johansson H, Oden A, Johnell O et al (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19:906–913PubMedCrossRefGoogle Scholar
  35. 35.
    Kanis JA, Johansson H, Oden A et al (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049–1054PubMedCrossRefGoogle Scholar
  36. 36.
    McCloskey EV, Johansson H, Oden A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811–817PubMedCrossRefGoogle Scholar
  37. 37.
    McCloskey EV, Lewiecki M, Kanis JA et al (2011) Denosumab reduces the risk of clinical osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®. Osteoporos Int 22(supplement 1):S103Google Scholar
  38. 38.
    Kanis JA, Johansson H, Oden A et al (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729–735PubMedCrossRefGoogle Scholar
  39. 39.
    Kanis JA, Johansson H, Oden A et al (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®). Osteoporos Int 22:2347–2355PubMedCrossRefGoogle Scholar
  40. 40.
    Kanis JA, Johansson H, Oden A et al (2011) Erratum to: A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®). Osteoporos Int 22:2357–2358CrossRefGoogle Scholar
  41. 41.
    Donaldson MG, Cawthon PM, Lui LY et al (2009) Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res 24:675–680PubMedCrossRefGoogle Scholar
  42. 42.
    Donaldson MG, Cawthon PM, Lui LY et al (2010) Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res 25:1506–1511PubMedCrossRefGoogle Scholar
  43. 43.
    Berry SD, Kiel DP, Donaldson MG et al (2010) Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int 21:53–60PubMedCrossRefGoogle Scholar
  44. 44.
    Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793–800PubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011

Authors and Affiliations

  • W. D. Leslie
    • 1
    Email author
  • S. Morin
    • 2
  • L. M. Lix
    • 3
  • H. Johansson
    • 4
  • A. Oden
    • 4
  • E. McCloskey
    • 5
  • J. A. Kanis
    • 6
  • for the Manitoba Bone Density Program
  1. 1.Department of Medicine (C5121)University of ManitobaWinnipegCanada
  2. 2.McGill UniversityMontrealCanada
  3. 3.University of SaskatchewanSaskatoonCanada
  4. 4.GothenburgSweden
  5. 5.Osteoporosis CentreNorthern General HospitalSheffieldUK
  6. 6.WHO Collaborating Centre for Metabolic Bone DiseasesUniversity of SheffieldSheffieldUK

Personalised recommendations